BCIQ Profiles

Company Profile Report

Imidazopyrimidine-based inhibitor of Leishmania proteasome identified to treat visceral leishmaniasis

DISEASE CATEGORY: Infectious disease

INDICATION: Leishmaniasis

Cell culture, in vitro, mouse, rat and dog studies identified an imidazopyrimidine-based inhibitor of Leishmania proteasome that

Read the full 218 word article

How to gain access

Continue reading with a
two-week free trial.